Supplementary Data1 from The Impact of <i>JAK1</i> Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer
Erica V. Carballo(Vanderbilt University Medical Center), Courtney A. Penn(Vanderbilt University Medical Center), Dandi Huang(Billings Clinic), Julia Wulfkuhle(University of California, San Francisco), Paula I. González-Ericsson(Breast Cancer Research Foundation), Violeta Sánchez(Vanderbilt University), Justin Steele(Vanderbilt University), Susan R. Opalenik(Vanderbilt University), Rosa I. Gallagher(George Mason University), Brian D. Lehmann(Vanderbilt University Medical Center), Brandie C. Taylor(Vanderbilt University Medical Center), Katherine Kleinberg(Vanderbilt University Medical Center), B.J. Rimel(Cedars-Sinai Medical Center), Justin M. Balko(Vanderbilt University Medical Center), Christina Maxey(Cedars-Sinai Medical Center), J Marshall(Vanderbilt University), Andres A. Ocampo(Vanderbilt University Medical Center), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Xiaopeng Sun(Vanderbilt University Medical Center)
Cited by 0
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
|The Lancet Oncology|2014|586